ATE250621T1 - Oral aktive a1 adenosin rezeptor agonisten - Google Patents

Oral aktive a1 adenosin rezeptor agonisten

Info

Publication number
ATE250621T1
ATE250621T1 AT00932688T AT00932688T ATE250621T1 AT E250621 T1 ATE250621 T1 AT E250621T1 AT 00932688 T AT00932688 T AT 00932688T AT 00932688 T AT00932688 T AT 00932688T AT E250621 T1 ATE250621 T1 AT E250621T1
Authority
AT
Austria
Prior art keywords
receptor agonists
adenosine receptor
oral active
oral
active
Prior art date
Application number
AT00932688T
Other languages
English (en)
Inventor
Brent K Blackburn
Chris Melville
Jeff A Zablocki
Venkata P Palle
Elfatih O Elzein
Lisa Wang
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE250621T1 publication Critical patent/ATE250621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00932688T 1999-05-24 2000-05-19 Oral aktive a1 adenosin rezeptor agonisten ATE250621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/317,523 US6576619B2 (en) 1999-05-24 1999-05-24 Orally active A1 adenosine receptor agonists
PCT/US2000/014036 WO2000071558A1 (en) 1999-05-24 2000-05-19 Orally active a1 adenosine receptor agonists

Publications (1)

Publication Number Publication Date
ATE250621T1 true ATE250621T1 (de) 2003-10-15

Family

ID=23234062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932688T ATE250621T1 (de) 1999-05-24 2000-05-19 Oral aktive a1 adenosin rezeptor agonisten

Country Status (19)

Country Link
US (1) US6576619B2 (de)
EP (1) EP1181302B1 (de)
JP (2) JP2003520776A (de)
KR (1) KR100537032B1 (de)
CN (1) CN1183153C (de)
AR (1) AR035909A1 (de)
AT (1) ATE250621T1 (de)
AU (1) AU760658B2 (de)
BR (1) BR0010882A (de)
CA (1) CA2375040C (de)
DE (1) DE60005507T2 (de)
ES (1) ES2206238T3 (de)
IL (2) IL146471A0 (de)
MX (1) MXPA01012038A (de)
NO (1) NO320854B1 (de)
NZ (1) NZ515580A (de)
TW (1) TW593330B (de)
WO (1) WO2000071558A1 (de)
ZA (1) ZA200109626B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
CA2476683C (en) * 2002-02-19 2011-11-01 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
CA2483827C (en) * 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
CA2654371A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Therapeutic compounds
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
CN101712709A (zh) * 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
JP7719769B2 (ja) 2019-09-11 2025-08-06 ザ スクリプス リサーチ インスティテュート 抗ウイルスプロドラッグ及びその医薬組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460929A1 (de) 1974-12-21 1976-06-24 Boehringer Sohn Ingelheim Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
DE3138397A1 (de) 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
CA1255297A (en) 1984-10-26 1989-06-06 Bharat Trivedi N.sup.6-benzopyrano and benzothiopyrano adenosines
US4593019A (en) 1984-10-26 1986-06-03 Warner-Lambert Company N6 -tricyclic adenosines
AU8274187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
US4954504A (en) 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
DE3855513T2 (de) * 1987-10-28 1997-01-09 Pro Neuron Inc Acyl deoxyribonukleosid-derivate und deren verwendungen
US4980379A (en) 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
DE8817122U1 (de) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
WO1990009178A1 (en) 1989-01-31 1990-08-23 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5017578A (en) 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5432164A (en) 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
DE4205306B4 (de) 1992-02-21 2005-11-24 Glüsenkamp, Karl-Heinz, Dr. Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994016702A1 (fr) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
EP0708781B1 (de) 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A3 -adenosin -rezeptor agonisten
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CN1390228A (zh) 2003-01-08
US20020091099A1 (en) 2002-07-11
AR035909A1 (es) 2004-07-28
US6576619B2 (en) 2003-06-10
ZA200109626B (en) 2004-03-10
DE60005507T2 (de) 2004-06-24
NO20015662D0 (no) 2001-11-20
DE60005507D1 (de) 2003-10-30
NO320854B1 (no) 2006-02-06
AU5037600A (en) 2000-12-12
CA2375040A1 (en) 2000-11-30
EP1181302A1 (de) 2002-02-27
JP2003520776A (ja) 2003-07-08
TW593330B (en) 2004-06-21
WO2000071558A1 (en) 2000-11-30
IL146471A (en) 2007-06-03
NZ515580A (en) 2004-06-25
IL146471A0 (en) 2002-07-25
CN1183153C (zh) 2005-01-05
AU760658B2 (en) 2003-05-22
CA2375040C (en) 2006-02-07
BR0010882A (pt) 2002-06-11
MXPA01012038A (es) 2002-05-06
KR20020092777A (ko) 2002-12-12
JP2006348040A (ja) 2006-12-28
EP1181302B1 (de) 2003-09-24
NO20015662L (no) 2002-01-23
ES2206238T3 (es) 2004-05-16
KR100537032B1 (ko) 2005-12-16

Similar Documents

Publication Publication Date Title
DE69825779D1 (de) Adenosin a1-rezeptor agonisten
DE69815378D1 (de) Adenosin a1-rezeptor agonisten
DE69825780D1 (de) Adenosin a1-rezeptor agonisten
PT1189916E (pt) N-pirazole agonistas do receptor a2a
DE60002722D1 (de) C-pyrazol a2a rezeptor agonisten
ATE293627T1 (de) Adenosin a2a rezeptor antagonisten
ATA904399A (de) Adenosin a3-rezeptor-modulatoren
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
ATE453647T1 (de) Adenosin a2a rezeptor antagonisten
PT1090019E (pt) Derivados de adenosina
DK1261322T3 (da) Farmaceutiske sammensætninger omfattende en adenosinreceptoragonist eller antagonist
DK2332915T3 (da) beta2-Adrenoceptoragonister
DK1233973T3 (da) Partielle eller fulde A1-agonister-N6-heterocykliske 5'-thiosubstituerede adenosinderivater
DE60008372D1 (de) Pharmazeutisch aktive verbindungen
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
NO20020979D0 (no) Selektive A2B-adenosin reseptorantagonister
DE60005507D1 (de) Oral aktive a1 adenosin rezeptor agonisten
IL127947A0 (en) Pharmaceutical use of adenosine agonists
ID30056A (id) Agonis-agonis 5-htif
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
DK1114323T3 (da) Cobalamin-assay
SE9903833D0 (sv) Kolhydratanvändning

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties